Article Text

FRI0041 In vivo monitoring of anti-folate therapy in arthritic rats using [18f]fluoro-peg-folate and pet
  1. DMSH Chandrupatla1,
  2. CJ van der Laken1,
  3. R Vos2,
  4. M Verlaan2,
  5. R van Kooij2,
  6. AD Windhorst2,
  7. Q Chen3,
  8. PS Low3,
  9. AA Lammertsma2,
  10. G Jansen1,
  11. CFM Molthoff2
  1. 1Amsterdam Rheumatology and immunology Centre – location VUmc
  2. 2Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands
  3. 3Department of Chemistry, Purdue University, West Lafayette, United States


Background Macrophages play a key role in the pathophysiology of rheumatoid arthritis (RA). The folate receptor β (FR-β) is expressed on these macrophages [1] and [18F]fluoro-PEG-folate positron emission tomography ([18F]fluoro-PEG-folate PET) can be used to visualize arthritis in vivo [2]. In addition, [18F]fluoro-PEG-folate PET could be a highly interesting tool for therapeutic monitoring of MTX therapy, the corner stone for RA therapy.

Objectives To study the potential of [18F]fluoro-PEG-folate PET for monitoring response to MTX in a rat model of RA.

Methods Arthritic rats [3] (n=3–6 per group) received interventions with either MTX [i.p., 1mg/kg; 2 times (group A) or 4 times (group B)] or PBS (control group)] with a time interval of 3–4 days. Healthy rats didn't receive any arthritic induction or MTX therapy. [18F]fluoro-PEG-folate PET-CT were acquired for one hour after tracer injection [2]. Scans were analysed using the region of interest method and standardized uptake values (SUVs) were determined (50–60 min time frame). Sixty minutes after the PET scan, ex-vivo tissue distribution was performed and the amount of radioactivity measured in a gamma counter (expressed as percentage of the injected dose/gram tissue (%ID/g)) [2]. For histopathology (Haematoxylin-Eosin (HE) and immunohistochemistry with macrophage specific antibodies ED1 (∼CD68) and ED2 (∼CD163) were applied. Synovial macrophages were counted in predefined areas of the knees [3].

Results PET scans clearly visualized significantly lower SUVs (1.5-fold, p<0.01) in arthritic knees of both MTX-treated groups, approximating the levels observed in healthy rats. Corroborating [18F]fluoro-PEG-folate PET, ex vivo tissue distribution [18F]fluoro-PEG-folate demonstrating a 2- and 4-fold decrease (group A and B, respectively) in tracer uptake in arthritic knees after MTX therapy (0.12 and 0.06 for groups A and B, and 0.22%ID/g for controls, respectively) (Figure). This reduction in uptake of [18F]fluoro-PEG-folate in arthritic knees was also associated with a significant decrease in ED1 and ED2 positive synovial macrophages in arthritic knees (∼4 fold) for both treated groups compared with control rats knees (p<0.01).

Conclusions This study in arthritic rats underscores the potential and usefulness of [18F]fluoro-PEG-folate PET as tool to monitor of MTX therapy and potentially other anti-folate treatments of RA.


  1. Van der Heijden et al, Arthr & Rheum (2009).

  2. Gent et al, Arthr Res Ther (2013).

  3. Chandrupatla et al, BioMed Res Int (2015).


Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.